

Matthew J Loza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6515347/publications.pdf>

Version: 2024-02-01

58
papers

3,221
citations

172457

29
h-index

175258

52
g-index

58
all docs

58
docs citations

58
times ranked

4499
citing authors

#	ARTICLE	IF	CITATIONS
1	Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study. <i>European Respiratory Journal</i> , 2022, 59, 2101733.	6.7	13
2	Clinical and transcriptomic features of persistent exacerbation-prone severe asthma in U-BIOPRED cohort. <i>Clinical and Translational Medicine</i> , 2022, 12, e816.	4.0	11
3	Instability of sputum molecular phenotypes in U-BIOPRED severe asthma. <i>European Respiratory Journal</i> , 2021, 57, 2001836.	6.7	13
4	Type 2-low asthma phenotypes by integration of sputum transcriptomics and serum proteomics. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 380-383.	5.7	20
5	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. <i>RMD Open</i> , 2021, 7, e001679.	3.8	19
6	Cohort profile of a US military population for evaluating pre-disease and disease serological biomarkers in rheumatoid and reactive arthritis: Rationale, organization, design, and baseline characteristics. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100522.	1.1	6
7	Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 577-590.	2.9	140
8	Contribution of airway eosinophils in airway wall remodeling in asthma: Role of MMP-10 and MET. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1102-1112.	5.7	32
9	Responsiveness of Serum C-reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-blind, Placebo-controlled Trials. <i>Arthritis and Rheumatology</i> , 2019, 71, 1660-1669.	5.6	13
10	I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment. <i>PLoS Computational Biology</i> , 2019, 15, e1006951.	3.2	18
11	Combined Blockade of TNF- α and IL-17A Alleviates Progression of Collagen-Induced Arthritis without Causing Serious Infections in Mice. <i>Journal of Immunology</i> , 2019, 202, 2017-2026.	0.8	22
12	SAT0103...LONGITUDINAL PRE-DISEASE TO DISEASE SERUM SAMPLES IDENTIFY BIOMARKERS THAT ARE UPREGULATED PRIOR TO THE DIAGNOSIS OF RHEUMATOID ARTHRITIS. , 2019, , .		0
13	IL-2-high in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. <i>European Respiratory Journal</i> , 2019, 53, 1800938.	6.7	104
14	Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. <i>European Respiratory Journal</i> , 2018, 51, 1702173.	6.7	67
15	Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 21-29.	0.9	96
16	Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 560-570.	2.9	166
17	Pathway discovery using transcriptomic profiles in adult-onset severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1280-1290.	2.9	105
18	Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 710-719.	2.9	57

#	ARTICLE	IF	CITATIONS
19	T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. <i>European Respiratory Journal</i> , 2017, 49, 1602135.	6.7	283
20	Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1602298.	6.7	44
21	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1797-1807.	2.9	236
22	A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 443-455.	5.6	165
23	Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. <i>Respiratory Research</i> , 2016, 17, 165.	3.6	107
24	Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study. <i>European Respiratory Journal</i> , 2016, 48, 1307-1319.	6.7	44
25	Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (<sc>CANTO</sc> 5825) in an ascending single-dose first-in-human study. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1289-1298.	2.4	16
26	Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2012, 13, 12.	3.6	26
27	Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 834.	2.9	1
28	T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus. <i>Cellular Immunology</i> , 2011, 271, 110-117.	3.0	31
29	Inflammatory Profile and Response to Anti-Tumor Necrosis Factor Therapy in Patients with Chronic Pulmonary Sarcoidosis. <i>Vaccine Journal</i> , 2011, 18, 931-939.	3.1	44
30	Asthma and gender impact accumulation of T cell subtypes. <i>Respiratory Research</i> , 2010, 11, 103.	3.6	15
31	Regulation of T cells in airway disease by beta-agonist. <i>Frontiers in Bioscience - Scholar</i> , 2010, S2, 969-979.	2.1	9
32	Glucocorticoid- and Protein Kinase A-Dependent Transcriptome Regulation in Airway Smooth Muscle. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2009, 41, 24-39.	2.9	39
33	Genetic and epigenetic inactivation of <i>TNFRSF10C</i> in human prostate cancer. <i>Prostate</i> , 2009, 69, 327-335.	2.3	25
34	Interactive effects of steroids and β -agonists on accumulation of type 2 T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 750.e1-755.e3.	2.9	13
35	Association between Q551R IL4R genetic variants and atopic asthma risk demonstrated by meta-analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 578-585.	2.9	45
36	β -Agonist enhances type 2 T-cell survival and accumulation. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 235-244.	2.9	29

#	ARTICLE	IF	CITATIONS
37	Assembly of Inflammation-Related Genes for Pathway-Focused Genetic Analysis. PLoS ONE, 2007, 2, e1035.	2.5	89
38	Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells. Blood, 2006, 107, 2052-2060.	1.4	67
39	A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate, 2006, 66, 1556-1564.	2.3	47
40	Purification of Peripheral Blood Natural Killer Cells. , 2005, 107, 147-162.		5
41	Natural Killer Cells. , 2005, , 257-267.		1
42	Human peripheral CD2 ^{hi} /lo T cells: an extrathymic population of early differentiated, developing T cells. International Immunology, 2005, 17, 1213-1225.	4.0	9
43	Peripheral NK cell phenotypes: multiple changing of faces of an adapting, developing cell. Molecular Immunology, 2005, 42, 385-395.	2.2	50
44	The IL-12 Signature: NK Cell Terminal CD56 ⁺ high Stage and Effector Functions. Journal of Immunology, 2004, 172, 88-96.	0.8	104
45	Differential regulation of NK cell proliferation by type I and type II IFN. International Immunology, 2004, 16, 23-32.	4.0	14
46	Multiple Color Immunofluorescence for Cytokine Detection at the Single-Cell Level. Molecular Biotechnology, 2003, 23, 245-258.	2.4	15
47	Accumulation of type 2 cytokine ⁺ T cells: differentiation-independent proliferation of pre-existing type 2 T cells. European Journal of Immunology, 2003, 33, 939-949.	2.9	8
48	Linear '2 nd ' lymphocyte development: hypotheses on cellular bases for immunity. Trends in Immunology, 2003, 24, 235-241.	6.8	32
49	Peripheral Immature CD2 ^{hi} /low T Cell Development from Type 2 to Type 1 Cytokine Production. Journal of Immunology, 2002, 169, 3061-3068.	0.8	22
50	Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood, 2002, 99, 1273-1281.	1.4	103
51	Distinction between IL-13 ⁺ and IFN- γ ⁺ natural killer cells and regulation of their pool size by IL-4. European Journal of Immunology, 2002, 32, 413-423.	2.9	41
52	NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production. European Journal of Immunology, 2002, 32, 3453-3462.	2.9	54
53	Distinction between IL-13 ⁺ and IFN- γ ⁺ natural killer cells and regulation of their pool size by IL-4. , 2002, 32, 413.		1
54	Final steps of natural killer cell maturation: a model for type 1 th type 2 differentiation?. Nature Immunology, 2001, 2, 917-924.	14.5	159

#	ARTICLE	IF	CITATIONS
55	Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells. Journal of Immunology, 2001, 167, 3114-3122.	0.8	315
56	B-Myb Overexpression Results in Activation and Increased Fas/Fas Ligand-Mediated Cytotoxicity of T and NK Cells. Journal of Immunology, 2001, 167, 242-249.	0.8	7
57	Multiple Color Immunofluorescence for Cytokine Detection at the Single Cell Level. , 2000, 121, 193-209.		3
58	Serological Biomarkers of Progression towards Diagnosis of Rheumatoid Arthritis in Active Component Military Personnel. Arthritis and Rheumatology, 0, , .	5.6	1